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18F-AV-1451 tau PET imaging correlates
strongly with tau neuropathology in
MAPT mutation carriers
Ruben Smith,1,2 Andreas Puschmann,1,2 Michael Scho¨ll,3,4 Tomas Ohlsson,5
John van Swieten,6 Michael Honer,7 Elisabet Englund8 and Oskar Hansson3,9
Tau positron emission tomography ligands provide the novel possibility to image tau pathology in vivo. However, little is known about
how in vivo brain uptake of tau positron emission tomography ligands relates to tau aggregates observed post-mortem. We performed
tau positron emission tomography imaging with 18F-AV-1451 in three patients harbouring a p.R406W mutation in the MAPT gene,
encoding tau. This mutation results in 3- and 4-repeat tau aggregates similar to those in Alzheimer’s disease, and many of the mutation
carriers initially suffer from memory impairment and temporal lobe atrophy. Two patients with short disease duration and isolated
memory impairment exhibited 18F-AV-1451 uptake mainly in the hippocampus and adjacent temporal lobe regions, correlating with
glucose hypometabolism in corresponding regions. One patient died after 26 years of disease duration with dementia and behavioural
deﬁcits. Pre-mortem, there was 18F-AV-1451 uptake in the temporal and frontal lobes, as well as in the basal ganglia, which strongly
correlated with the regional extent and amount of tau pathology in post-mortem brain sections. Amyloid-b (18F-ﬂutemetamol) positron
emission tomography scans were negative in all cases, as were stainings of brain sections for amyloid. This provides strong evidence that
18F-AV-1451 positron emission tomography can be used to accurately quantify in vivo the regional distribution of hyperphosphorylated
tau protein.
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Introduction
Tau pathology is closely related to neuronal dysfunction
and degeneration in Alzheimer’s disease and other tauopa-
thies. In these disorders, tau is abnormally hyperpho-
sphorylated and accumulates intracellularly, forming
tangles of paired helical ﬁlaments (PHF), twisted ribbons
and/or straight ﬁlaments (Iqbal et al., 2016). Tau aggre-
gates in Alzheimer’s disease consist predominantly of
PHF, which contain all six isoforms of tau, mixed with
straight ﬁlaments. The recent development of PET radio-
tracers for tau aggregates opens up the possibility to assess
tau pathology in vivo (Ossenkoppele et al., 2015;
Villemagne and Okamura, 2015; Harada et al., 2016;
Johnson et al., 2016; Scholl et al., 2016; Smith et al.,
2016). These tracers, along with PET tracers revealing
extracellular plaques containing amyloid-b ﬁbrils, will be
essential for improving the early diagnosis of Alzheimer’s
disease in clinical practice as well as in the evaluation of
novel disease-modifying therapies (Dani et al., 2016).
Studies using the most common PET tracer for tau path-
ology to date, 18F-AV-1451, demonstrated increased
uptake in temporo-parietal regions in patients with
Alzheimer’s disease (Chien et al., 2013; Johnson et al.,
2016; Ossenkoppele et al., 2016; Smith et al., 2016). In
post-mortem brain tissue, this ligand was screened to
detect PHFs of tau, exhibiting a 425-fold higher afﬁnity
for PHF-tau compared to amyloid-b ﬁbrils (Xia et al.,
2013). Recently, an autoradiography study reported prefer-
ential in vitro binding of 18F-AV-1451 to PHFs in
Alzheimer’s disease, not to straight ﬁlaments resulting
from other tauopathies (Marquie et al., 2015). However,
no study has hitherto compared regional in vivo binding of
a tau PET tracer with the distribution and the degree of tau
pathology using post-mortem immunohistochemistry in the
same individual.
Individuals exhibiting only tau pathology, not amyloid-b
ﬁbrils, are an ideal group to further explore the binding
properties of a tau PET tracer. The p.R406W mutation in
the gene encoding the tau protein (MAPT c.1216C4T;
R406W) on chromosome 17 results in neuroﬁbrillary tan-
gles that are similar to the neuroﬁbrillary tangles in
Alzheimer’s disease at an ultrastructural level (Ghetti
et al., 2015). Many cases with this mutation present with
slowly progressive episodic memory impairment, which in
many ways clinically resembles Alzheimer’s disease (Ostojic
et al., 2004; Passant et al., 2004). Previous neuropatho-
logical examination of R406W mutation carriers revealed
tau-positive neuroﬁbrillary tangles and neurites. These
PHF-tau changes were mainly localized in temporal and
frontal lobe areas as well as the basal ganglia, sparing
the parietal and occipital lobes (Lindquist et al., 2008;
Ghetti et al., 2015).
Here we report the ﬁrst results of 18F-AV-1451 (tau),
18F-ﬂutemetamol (amyloid-b) and 18F-ﬂuorodeoxyglucose
(FDG, glucose metabolism) PET imaging in three patients
carrying the MAPT R406W mutation at different disease
stages. In addition, we report results from the neuropatho-
logical examination of one of these subjects who died 2
weeks after the PET scans, as well as the relationship be-
tween in vivo and post-mortem assessment of tau path-
ology in this case. Finally, autoradiography using
3H-AV1451 was performed on cortical tissue sections




Three subjects carrying the MAPT R406W mutation, aged 56,
60 and 76 years, (Patients A, B and C, respectively) from a
family with hereditary dementia from Southern Sweden were
investigated. Four control subjects and ﬁve patients with
Alzheimer’s disease were recruited from the ongoing Swedish
Bioﬁnder Study (www.bioﬁnder.se). Further information on
the clinical assessments is given in the Supplementary material.
All clinical data are summarized in Table 1. Written informed
consent was obtained from the participants, and approval of
this study was obtained from the Regional Ethical Review
Board in Lund, Sweden.
MRI and CT scan
Patients A and B underwent a 3 T MRI scan using a Siemens
Skyra scanner. T1-weighted magnetization-prepared rapid gra-
dient echo (T1-MPRAGE) was acquired at a resolution of
1  1  1mm. Patient C could not undergo MRI due to claus-
trophobia and consequently underwent a CT scan, using a
Philips Brilliance 64 scanner. Images were reconstructed to
5mm axial and 3mm coronal slices.
PET
18F-AV-1451 PET scans were performed on a GE Discovery
690 PET scanner (General Electric Medical Systems) as dy-
namic scans using LIST-mode 100–120min after a bolus in-
jection of 365  14 MBq of 18F-AV-1451. 18F-FDG scans
were acquired on the same scanner in a static scan
60–80min after injection of 198  2 MBq of FDG. Images
of 18F-ﬂutemetamol (Nelissen et al., 2009) were obtained as
dynamic scans 90–110min after injection of 193  2 MBq on
a Philips Gemini TF PET-CT scanner (Philips Medical
Systems). Low dose CT scans for attenuation correction were
performed immediately prior to the PET scans. PET data were
reconstructed into 5min frames using an iterative Vue Point
HD algorithm with six subsets, 18 iterations with 3mm ﬁlter
and no time-of-ﬂight correction. 18F-ﬂutemetamol data were
processed using NeuroMarQ software (GE Healthcare), ana-
lyses of 18F-AV-1451 and 18F-FDG data were performed using
PMOD 3.603 software (Pmod, Zurich, Switzerland). PET
images were co-registered to their corresponding magnetic res-
onance T1-MPRAGE or CT images. We chose to analyse the
18F-AV-1451 standardized uptake value ratios (SUVRs) from
the same areas that were processed for neuropathological ana-
lysis in Patient C, with the addition of a few areas in the
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temporal and frontal lobes and the basal ganglia, areas known
to be affected by pathology in R406W mutation carriers.
Regions of interest were delineated manually for the data pre-
sented in Figs 1 and 3. Regions of interest were delineated on
the magnetic resonance images (Patients A and B, as well as
control subjects and cases with Alzheimer’s disease) or CT
image (Patient C) and transformed into PET space using trans-
formations derived from co-registrations. The cerebellar cortex
was used as a reference region for the calculation of SUVRs.
For the analysis of correlations between regional 18F-FDG
SUVRs and 18F-AV-1451 SUVRs in Patients A and B (Fig. 2),
the MRI was segmented into grey and white matter and re-
gions of interest were deﬁned using FreeSurfer (version 5.3 and
its Desikan-Killiany Atlas). PET images were co-registered to
the MRIs and SUVRs calculated in PET space. The cerebellar
cortex was also here used as a reference region for the calcu-
lation of SUVRs. Further, the SUVRs of the 18F-FDG scans
were normalized to the mean control 18F-FDG value for each
neocortical region in order to relate the tau pathology to the
relative change of the 18F-FDG uptake in Patients A and B,
respectively (Smith et al., 2016).
Neuropathology
Neuropathological diagnostic analysis was performed on sec-
tions including the hippocampus, the inferior and superior
temporal gyri, the frontal pole and the dorsolateral frontal
gyri, the parietal cortex, occipital cortex and cerebellum.
Details of immunohistochemical procedures are described in
the Supplementary material. Neurodegenerative structural
changes were assessed as to regional extent, local–regional se-
verity and to intensity/density of protein pathology, with
regard to tau appearance. Tau pathology in the cortical com-
partment was readily graded in none, mild, moderate, and
severe (grades 0, + , + + and + + + , respectively), for correl-
ation with 18F-AV-1451 uptake. Mild grade ( + ) corresponded
with few loosely knit aggregates of tau-positive ﬁbres in one or
two cortical layers, mostly the laminae II–III, and a few dis-
persed tau-positive neurites between the aggregates. Moderate
grade ( + + ) signiﬁed scattered loosely knit ﬁbre aggregates in
all layers, with tau-positive scattered neurites and occasional
tangle-ﬁlled neurons in-between. In severe grade ( + + + ),
abundant aggregates were seen in all layers, with numerous
tau-positive neurites and several tau-positive tangle-ﬁlled neu-
rons in-between. Inter-rater reliability was determined by three
independent, blinded readers (Cohen’s kappa, 0.72–0.84;
P5 0.001; SPSS version 22). As a second independent measure
of tau-positive neurite density, the number of neurites/mm was
estimated in the cortex of tau-stained sections using stereolo-
gical systematic random sampling (Ronn et al., 2000) (Stereo
Investigator, MBF Bioscience). Only cortical areas and the pu-
tamen could be reliably sampled using this stereological
approach.
Autoradiography
Details of the methods regarding autoradiography are
described in the Supplementary material.
Statistical analyses
Correlations between neurite density, the neuropathological
grade of tau pathology and 18F-AV-1451 SUVR values as
well as the correlation between 18F-FDG and 18F-AV-1451
SUVR were analysed with non-parametric Spearman’s Rank-
Order Correlation using Graph Pad Prism 6. A P-value
of5 0.05 was considered statistically signiﬁcant.
Results
Study subjects
The three examined patients belonged to two generations
of a family with slowly progressive dementia; all carried the
MAPT R406W mutation. Cognitive testing of Patients A
and B revealed an isolated memory impairment (Table 1),
and both fulﬁlled the criteria of mild cognitive impairment
(Petersen, 2004). Patient A had a 10-year history of isolated
short-term memory loss and irritability and Patient B had
developed mild memory impairment and increased anxiety
Table 1 Clinical characteristics of study participants
Case A Case B Case C Controls (n = 4)
Age at examination (years) 60 56 76 71.5  7
Gender M F F 2M / 2F
Disease duration (years) 10 4 26 N/A
Genotype MAPT c.1216C4T (het) MAPT c.1216C4T (het) MAPT c.1216C4T (het) N/A
MMSE 26 24 N/T 28.75  1.5
Memory delayed recall (ADAS) 8 10 N/T 1.25  1
AQT (s) 57 68 N/T 61  13
SDMT 32 42 N/T 37  10
Stroop (s) 18 24 N/T 19  3
TMT-A (s) 55 49 N/T 37  12
Letter S-fluency 25 14 N/T 15  6
Animal fluency 26 20 N/T 24  5
ADAS 3 = Alzheimer’s Disease Assessment Acale, part 3; AQT (C + S = Colour + Shape) = A Quick Test of Cognitive Speed; MMSE = Mini-Mental State Examination; N/A = not
available; N/T = unable to complete testing; SDMT = Symbol Digit Modalities Test; Stroop = Stroop Color-Word Test; TMT-A = Trail Making Test, part A.
For all tests except ADAS, AQT, Stroop and TMT, a lower value reflects higher degree of cognitive dysfunction.
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4 years prior to the clinical examination. MRI in both cases
showed no or slight general brain atrophy with moderate
atrophy in the medial temporal lobes, most pronounced in
the parahippocampal gyri with widening of the collateral
sulci, and a medial temporal atrophy corresponded to
Scheltens score 1. Patient C exhibited memory impairment
26 years prior to this examination and had developed
marked dementia, behavioural disturbances, mutism, dys-
phagia and mild parkinsonism by the time of this study.
The CT scan showed generalized cortical atrophy with sub-
stantial atrophy of the medial temporal lobes, especially of
the parahippocampal gyri with pronounced widening of the




In the two younger cases (Patients A and B; Fig. 1A, B and
I), retention of 18F-AV-1451 was most distinct in the tem-
poral poles, the hippocampus and anterior aspects of the
inferior temporal gyrus. Uptake was also detected in the
basal regions of the frontal lobes. In the more affected
case (Patient C, Fig. 1C and I), a more widespread reten-
tion pattern was observed in the temporal lobes, the basal
ganglia and the frontal lobes. No signiﬁcant tracer uptake
was detected in the parietal or occipital lobes. Control cases
showed no tracer retention in cortical areas (Fig. 1D and
Supplementary Fig. 1).
The patients further underwent 18F-ﬂutemetamol PET
scans. Composite scores representing mean global cortical
uptake were below a previously determined cut-off for
amyloid-b-positivity (51.42; Palmqvist et al., 2014) in
the three patients who did not show visual signs of cortical
18F-ﬂutemetamol retention either (Fig. 1E–G).
Correlation of 18F-AV-1451
with 18F-FDG
Patients A and B underwent an additional 18F-FDG scan.
The 18F-FDG SUVRs for each region were normalized to
the controls’ regional SUVRs and correlated with the cor-
responding AV-1451 SUVRs (Fig. 2A–D). We found stat-
istically signiﬁcant inverse relationships of higher regional
AV-1451 uptake with lower FDG retention in both
patients (Patient A: rs = 0.39, P50.01, Fig. 2E; Patient
B: rs = 0.37, P50.01, Fig. 2F).
Neuropathology
Patient C died 2 weeks after the PET examinations.
Immunohistochemical staining for hyperphosphorylated tau
protein showed extensive neuronal tau pathology in the tem-
poro-limbic region, the anterior temporal lobe and hippocam-
pus, where tau-positive neuroﬁbrillary tangles were abundant
along with tau-positive neurites. Lower-grade pathology was
detected in frontal cortical areas, whereas posterior cortical
areas were only affected to a minor degree. Tau pathology
was assessed according to a four-point grading system (0, + ,
+ + , + + + ), as described above, and results are summarized
in Fig. 3A–J. Both 3R and 4R tau-positive neurites could be
detected using isotype speciﬁc antibodies (data not shown).
No amyloid-b-containing neuritic plaques or amyloid angio-
pathy were detected (data not shown).
Non-parametric correlation analysis showed a statistic-
ally highly signiﬁcant positive correlation between
Figure 1 18F-AV-1451 and 18F-flutemetamol PET. (A–D)
18F-AV-1451 scans of tau mutation carriers A–C in panels A–C,
respectively. A representative control subject is shown in D. (E–H)
18F-flutemetamol PET. Patients A–C in panels E–G, respectively.
(H) A positive scan typical for a patient with Alzheimer’s disease.
The signal in A–C represents non-specific white matter binding.
Numbers below images indicate the composite score for global
cortical mean uptake. (I) SUVRs, expressed as per cent of control
values for (from left to right for each region) Patients A (red), B
(green), C (orange), and Alzheimer’s disease (AD) (blue). Patients
with Alzheimer’s disease are presented  standard error of the
mean.
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18F-AV-1451 SUVRs in different brain regions and the se-
verity of tau-neuropathology according to immunohisto-
chemistry in the same regions when using either
neuropathological grading of tau pathology (r = 0.93,
P50.01; Fig. 3I) or quantiﬁcation of the density of tau-
positive neurites (r = 0.92, P5 0.01; Fig. 3K). Interestingly,
the region with the highest SUVR (2.85) was putamen,
which did not exhibit higher tau pathology density than
the inferior temporal lobe with an SUVR of 2.38.
Autoradiography
Cortical tissue samples from two other patients with the
R406W MAPT mutation were analysed using autoradiog-
raphy. Speciﬁc binding of 3H-AV1451 to tau aggregates
could be detected in the cortical tissue sections of both
patients. Radioligand binding was co-localized with tau ag-
gregates, as visualized by immunohistochemistry with the
tau-speciﬁc antibody AT8 (Supplementary Fig. 2).
Discussion
In the present study we describe three members of a family
with MAPT R406W mutation at different stages of a
degenerative neurological disorder. In vivo imaging with
18F-AV-1451 PET indicated that tau pathology in these
cases starts in the inferior temporal lobes and temporal
poles, and at a later stage also involves the basal ganglia
and the frontal cortex while sparing posterior cortical areas
Figure 2 Correlation of 18F-FDG with 18F-AV-1451. (A–D) Images of Patient A. (A and C) Transverse and sagittal images of 18F-FDG,
scale showing range of SUVR values. (B and D) Transverse and sagittal images of 18F-AV-1451, scale showing range of SUVR values. (E and F)
Correlation between FDG and AV-1451 in Patients A (E) and B (F). Patient FDG-SUVRs have been normalized to control FDG-SUVR values for
each region. Line represents a linear regression.
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and the cerebellum. In one patient who died shortly after
PET scanning and was examined neuropathologically, we
found a strong positive correlation between the regional
in vivo retention of 18F-AV-1451 and the density of tau
aggregates visualized with immunohistochemistry in post-
mortem brain tissue. Our study is the ﬁrst to report
18F-AV-1451 PET signal being directly correlated to neuro-
pathological tau burden in the same individual, which pro-
vides strong evidence that in vivo 18F-AV-1451 PET
retention indeed reﬂects the density of tau pathology con-
sisting of PHFs. However, it is known that unspeciﬁc re-
tention of 18F-AV-1451 occurs in the striatum and choroid
plexus, for example (Scholl et al., 2016). It is therefore
interesting to note that the region with highest retention
of 18F-AV-1451 in Patient C was the putamen. The neuro-
pathological evaluation revealed relatively severe tau path-
ology in this region, but even greater pathological burden
was observed in the inferior temporal lobe, which exhibited
a slightly lower retention of 18F-AV-1451 (Fig. 3K), indi-
cating that a proportion of the signal in the putamen might
represent unspeciﬁc tracer retention in addition to the spe-
ciﬁc binding to tau aggregates.
The R406W mutation is located in the N-terminal exon
13 of the MAPT gene and causes the formation of agglom-
erations containing six isoforms of tau (including 3R and
4R tau) highly similar to the aggregates found in
Alzheimer’s disease (Hong et al., 1998; Ghetti et al.,
2015), which was corroborated in the present study.
Figure 3 18F-AV-1451 correlation with neuropathology. (A and B) Tau inclusions, grade + , at 4 (A) and 20 magnification (B). (C and
D) Grade + + , at 4 (C) and 20 magnification (D). Grade + + + , at 4 (E) and 20 magnification (F). (G) Cerebellar white matter and
cortex (grade 0) at 4 magnification. Inset at 20 magnification. (H) Positive control, cortex from a patient with Alzheimer’s disease at 20
magnification. Scale bars = 500 mm at 4 and 100 mm at 20 magnifications. (I) Correlation between 18F-AV-1451 and neuropathological grade.
Line represents a linear regression. Spearman correlation: rs = 0.93, P5 0.01. (J) Neuropathological grades in the brain regions analysed. (K)
Correlation of tau-positive neurite density and 18F-AV-1451 SUVR in the cortical regions analysed and the putamen. Line represents a linear
regression. Spearman correlation: rs = 0.92, P5 0.01.
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At an ultrastructural level the tau ﬁlaments are PHF and
straight ﬁlaments with a diameter of 8–20nm, structurally
similar to ﬁlaments found in Alzheimer’s disease (Reed
et al., 1997; Hutton et al., 1998). It has previously been
shown that 18F-AV-1451 can detect tau aggregates in pa-
tients with Alzheimer’s disease (Ossenkoppele et al., 2015;
Johnson et al., 2016; Smith et al., 2016). Our study pro-
vides proof of concept that it is also possible to visualize
tau pathology in R406W tau mutation carriers using
18F-AV-1451 PET. This is in accordance with a recent
study reporting highly concordant patterns of staining
with tau-antibody AT8 and 18F-AV-1451 binding in post-
mortem brain tissue of among others, Alzheimer’s disease
patients and subjects carrying MAPT mutations (Sander
et al., 2016), although this study also found evidence for
off-target binding and lack of correlation between antibody
staining and in vitro tracer binding in certain tau strains.
However, the present study indicates that the in vivo bind-
ing of 18F-AV-1451 correlates highly with the extent of tau
aggregates containing PHF. With tau immunization thera-
pies for Alzheimer’s disease currently emerging (Pedersen
and Sigurdsson, 2015), tau mutation carriers constitute
the ideal population for studying the effects of these thera-
pies. Not only would it be possible to examine the effects
of anti-tau treatment in the absence of concurrent amyloid-
b pathology, but also to identify and recruit subjects to
clinical trials at a presymptomatic disease stage. Our results
also suggest that one study endpoint in such clinical trials
could be 18F-AV-1451 retention.
Furthermore, we found an inverse relationship between
the retention of 18F-AV-1451 and brain glucose metabolism
as measured by 18F-FDG, indicative of decreased neuronal
metabolism and dysfunction in areas affected by tau path-
ology. These results indicate that tau-pathology is tightly
associated with neuronal dysfunction, which is in line with
previous publications on tau and glucose hypometabolism
in Alzheimer’s disease (Ossenkoppele et al., 2015; Smith
et al., 2016). Similarly, cognitive testing in Patients A and
B only showed deﬁcits restricted to memory, likely reﬂect-
ing the limited distribution of tau pathology and glucose
hypometabolism to the inferior and medial temporal lobes
in these two cases.
In conclusion, our results strongly support the notion
that in vivo 18F-AV-1451 PET reﬂects the intensity of
regional tau neuropathology. The level of 18F-AV-1451
retention correlates with glucose hypometabolism and neur-
onal dysfunction. Tau pathology in R406W mutation car-
riers can be visualized using 18F-AV-1451 PET, thus
providing a useful tool for monitoring the effects of
future therapies directed against the formation of tau-inclu-
sions in these patients.
Acknowledgements
We wish to acknowledge the contribution of Dr Olof
Strandberg, Dr Douglas Ha¨gerstro¨m and Dr Jonas Jo¨gi at
Ska˚ne University Hospital. The precursor of AV-1451 was
provided by Avid Radiopharmaceuticals and [18F]-ﬂuteme-
tamol was by GE Healthcare, but no funding was received
from the companies. The data were analysed and the
manuscript written independent from any company
interests.
Funding
The study was funded by the Swedish Research Council,
the European Research Council, the Swedish Brain
Foundation, the Swedish Alzheimer foundation, the
Trolle-Wachtmeister Foundation and the Swedish Federal
Government under the ALF Agreement.
Supplementary material
Supplementary material is available at Brain online.
References
Chien DT, Bahri S, Szardenings AK, Walsh JC, Mu F, Su MY, et al.
Early clinical PET imaging results with the novel PHF-tau radioli-
gand [F-18]-T807. J Alzheimers Dis 2013; 34: 457–68.
Dani M, Brooks DJ, Edison P. Tau imaging in neurodegenerative dis-
eases. Eur J Nucl Med Mol Imaging 2016; 43: 1139–50.
Ghetti B, Oblak AL, Boeve BF, Johnson KA, Dickerson BC, Goedert
M. Invited review: frontotemporal dementia caused by microtubule-
associated protein tau gene (MAPT) mutations: a chameleon for
neuropathology and neuroimaging. Neuropathol Appl Neurobiol
2015; 41: 24–46.
Harada R, Okamura N, Furumoto S, Furukawa K, Ishiki A, Tomita
N, et al. 18F-THK5351: a novel PET radiotracer for imaging neuro-
ﬁbrillary pathology in Alzheimer disease. J Nucl Med 2016; 57:
208–14.
Hong M, Zhukareva V, Vogelsberg-Ragaglia V, Wszolek Z, Reed L,
Miller BI, et al. Mutation-speciﬁc functional impairments in distinct
tau isoforms of hereditary FTDP-17. Science 1998; 282: 1914–17.
Hutton M, Lendon CL, Rizzu P, Baker M, Froelich S, Houlden H,
et al. Association of missense and 5’-splice-site mutations in tau with
the inherited dementia FTDP-17. Nature 1998; 393: 702–5.
Iqbal K, Liu F, Gong CX. Tau and neurodegenerative disease: the
story so far. Nat Rev Neurol 2016; 12: 15–27.
Johnson KA, Schultz A, Betensky RA, Becker JA, Sepulcre J, Rentz D,
et al. Tau PET imaging in aging and early Alzheimer’s disease. Ann
Neurol 2016; 79: 110–9.
Lindquist SG, Holm IE, Schwartz M, Law I, Stokholm J, Batbayli M,
et al. Alzheimer disease-like clinical phenotype in a family with
FTDP-17 caused by a MAPT R406W mutation. Eur J Neurol
2008; 15: 377–85.
Marquie M, Normandin MD, Vanderburg CR, Costantino IM, Bien
EA, Rycyna LG, et al. Validating novel tau positron emission tom-
ography tracer [F-18]-AV-1451 (T807) on postmortem brain tissue.
Ann Neurol 2015; 78: 787–800.
Nelissen N, Van Laere K, Thurfjell L, Owenius R, Vandenbulcke M,
Koole M, et al. Phase 1 study of the Pittsburgh compound B deriva-
tive 18F-ﬂutemetamol in healthy volunteers and patients with prob-
able Alzheimer disease. J Nucl Med 2009; 50: 1251–9.
Ossenkoppele R, Schonhaut DR, Baker SL, O’Neil JP, Janabi M,
Ghosh PM, et al. Tau, amyloid, and hypometabolism in a patient
with posterior cortical atrophy. Ann Neurol 2015; 77: 338–42.








ollege London user on 10 M
ay 2019
Ossenkoppele R, Schonhaut DR, Scholl M, Lockhart SN, Ayakta N,
Baker SL, et al. Tau PET patterns mirror clinical and neuroanatom-
ical variability in Alzheimer’s disease. Brain 2016; 139: 1151–67.
Ostojic J, Elfgren C, Passant U, Nilsson K, Gustafson L, Lannfelt L,
et al. The tau R406W mutation causes progressive presenile demen-
tia with bitemporal atrophy. Dement Geriatr Cogn Disord 2004; 17:
298–301.
Palmqvist S, Zetterberg H, Blennow K, Vestberg S, Andreasson U,
Brooks DJ, et al. Accuracy of brain amyloid detection in clinical
practice using cerebrospinal ﬂuid beta-amyloid 42: a cross-validation
study against amyloid positron emission tomography. JAMA Neurol
2014; 71: 1282–9.
Passant U, Ostojic J, Froelich Fabre S, Gustafson L, Lannfelt L,
Larsson EM, et al. Familial presenile dementia with bitemporal at-
rophy. Dement Geriatr Cogn Disord 2004; 17: 287–92.
Pedersen JT, Sigurdsson EM. Tau immunotherapy for Alzheimer’s dis-
ease. Trends Mol Med 2015; 21: 394–402.
Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern
Med 2004; 256: 183–94.
Reed LA, Grabowski TJ, Schmidt ML, Morris JC, Goate A, Solodkin
A, et al. Autosomal dominant dementia with widespread neuroﬁb-
rillary tangles. Ann Neurol 1997; 42: 564–72.
Ronn LC, Ralets I, Hartz BP, Bech M, Berezin A, Berezin V, et al. A
simple procedure for quantiﬁcation of neurite outgrowth based on
stereological principles. J Neurosci Methods 2000; 100: 25–32.
Sander K, Lashley T, Gami P, Gendron T, Lythgoe MF, Rohrer JD,
et al. Characterization of tau positron emission tomography
tracer [F]AV-1451 binding to postmortem tissue in Alzheimer’s
disease, primary tauopathies, and other dementias. Alzheimers
Dement 2016, doi: 10.1016/j.jalz.2016.01.003.
Scholl M, Lockhart SN, Schonhaut DR, O’Neil JP, Janabi M,
Ossenkoppele R, et al. PET imaging of tau deposition in the aging
human brain. Neuron 2016; 89: 971–82.
Smith R, Wibom M, Olsson T, Hagerstrom D, Jogi J, Rabinovici GD,
et al. Posterior accumulation of tau and concordant hypometabolism
in an early-onset Alzheimer’s disease patient with presenilin-1 mu-
tation. J Alzheimers Dis 2016; 51: 339–43.
Villemagne VL, Okamura N. Tau imaging in the study of ageing,
Alzheimer’s disease, and other neurodegenerative conditions. Curr
Opin Neurobiol 2015; 36: 43–51.
Xia CF, Arteaga J, Chen G, Gangadharmath U, Gomez LF, Kasi D,
et al. [(18)F]T807, a novel tau positron emission tomography ima-
ging agent for Alzheimer’s disease. Alzheimers Dement 2013; 9:
666–76.








ollege London user on 10 M
ay 2019
